Podcasts about Approved

In a shocking development that has radio hosts and political commentators buzzing, the State Department has approved UN General Assembly visas for top Iranian officials—including President Masoud Pezeshkian! We break down the high-stakes controversy, the outrage over foreign plot threats, and a wild, bold proposal to turn the tables at the airport. Plus, Dr. Steve Nail weighs in on South Carolina's $1.8B surplus and gas tax debates, alongside a breakdown of the Senate showdown over big tech AI data center energy costs!

Jack and Steven are back to talk about Jack officially securing his Drone Pilot license, Nike stock dropping, Apple's new releases (even though this was recorded before anything was officially announced), Mr. Beast's rap song, which direction the guys rotate their phones, and prosciutto. Also being hated by losers is the price you pay for not being one.

The Washington Supreme Court struck down Initiative 2066 in a 6-3 decision, ruling the voter-approved natural gas measure unconstitutional for covering four distinct subjects. The measure had passed with nearly 52% of the vote across 34 of Washington's 39 counties in 2024. Chief Justice Debra Stephens wrote that no portion could be severed and saved. https://www.clarkcountytoday.com/news/wa-high-court-tosses-natural-gas-measure-approved-by-voters/ #WashingtonState #Initiative2066 #NaturalGas #WashingtonSupremeCourt #EnergyPolicy #ClarkCounty #ClarkCountyToday

Brought to you by the English Programme. Featuring news, politics, popular culture, celebrity trivia, quizzes, book readings, and a whole host of fun.Support Our Rescue Cats | Our Blog | Get New Episodes By Email | Rumble | X | YouTube | NewsK365 on Spreaker | Get New Blog Posts By Email | Throne Wishlist |

Brought to you by the English Programme. Featuring news, politics, popular culture, celebrity trivia, quizzes, book readings, and a whole host of fun.Support Our Rescue Cats | Our Blog | Get New Episodes By Email | Rumble | X | YouTube | NewsK365 on Spreaker | Get New Blog Posts By Email | Throne Wishlist |

Whose fault is it that all the baristas and also everyone getting coffee in America are incompetent? Maya declares that the world is unlivable because it's impossible to get coffee. Producer Tyler is on a schedule here, people! Maya's neighbors are moving. Don't celebrate yet…there's a catch. Maya and Amy launch into the filthy gangster rap that raised them and all the murder mysteries surrounding the scene. Why did it take so long to find Tupac's murderer? Who killed Biggie? Why isn't anyone solving these mysteries? Amy has the deets. Is there anyone scarier than Suge Knight? The ladies have differing opinions about the Incredible Hulk. Is there anyone cornier or worse than Sean Puffy Combs? Maya can't believe that someone is named Keffe D. Amy really goes deep on this case. Biggie vs. Tupac…who is the greatest rapper of all time? Next up, postpartum psychosis. Then Approved/Denied MN State Fair Foods edition! Amy reviews the movie The End of Oak Street. It's a real roller coaster, people. Maya reviews The Last House. Amy gets back into Project Runway thanks to Viva Paper Towels. Maya talks creative process. Tim Gunn, we love you.  

The other day, the government of Israel approved the building of a new city in the Shomron to be called SHIRA, on Highway 5, east of Rosh HaAyin, on the way to the city of Ariel. Tens of thousands of apartments will be built. On 9,500 dunams of land that will be home to over 100,000 Jews. Eastern Gush Dan. Half an hour to Tel Aviv. Next to the train.This didn't happen by accident.Smotrich and Netanyahu. A partnership that has totally changed the map of Israel like never before. Approved over 100 new communities in Judea and Samaria. New cities. Around 160 farms reclaiming the land, stopping the illegal Palestinian Authority land grab backed by EU funding. What used to take twenty years now happens in weeks. Now Smotrich has announced doing the same thing in the Negev and Galil, two areas the Arabs have been taking over, making Jews the minority, with no government pushback. He will finally take care of that too. Anyone who knows the government bureaucracy, and the deep state power that has allowed the Arab takeover of the Galil and Negev, understands how many roadblocks Smotrich has to overcome. That is the revolution. That is the vision becoming facts on the ground.And it will stop the second Israelis hand the keys of government back over to deep state powers on the political left, today being led by Eizenkot.After October 7, after the massacre, after Nova, after the country burned, too many Israelis are still ready to vote for the bloc that would make Gadi Eisenkot prime minister. The same man who, as IDF Chief of Staff, hollowed out the army and sold the country the religion of containment, belittled the Jewish concept of rising up to kill those who want to kill you, and “quiet will be met with quiet.” That doctrine didn't give us peace. It gave our enemies years to train, tunnel, arm, and walk into our homes.Eisenkot is not a leader; he's a product. No spine, no charisma, no new thinking since October 7. Just the deep state's latest packaged “savior,” sold to the public as the great hope for replacing Netanyahu.You don't honor the murdered by putting the architects of weakness back in charge.You honor them by finishing the job: more cities, more farms, more Jews on the high ground, an army that deters instead of manages.Smotrich and Netanyahu delivered the building. The other side delivered the conception.If you want Shira and the next hundred communities, they need the votes. Momentum like this is a miracle. Stopping it would be a crime.Share this. The land is being built. We can't hand the country back to the same political left security leaders who preached and practiced appeasement and failed us miserably. We need leaders who know we are facing a jihadi enemy and who have the vision to strengthen a proud Jewish State of Israel.These are redemptive times. We are living miracles in real time. There will still be ups and downs, but the trajectory is up and up, and it is breathtaking.Strengthen your emunah in Hashem. Follow me at the Pulse of Israel and share these truths. Vote with that clarity in the coming elections.Am Yisrael Chai!!!Join Our Whatsapp Channel: https://chat.whatsapp.com/GkavRznXy731nxxRyptCMvFollow us on Twitter: https://x.com/AviAbelowJoin our Telegram Channel: https://t.me/aviabelowpulseFollow us on Instagram: https://www.instagram.com/pulse_of_israel/?hl=enPulse of Israel on Facebook: https://www.facebook.com/IsraelVideoNetworkVisit Our Website - https://pulseofisrael.com/Donate to Pulse of Israel: https://pulseofisrael.com/boost-this-video/

Ever notice how the beauty industry seems to profit most when you're the most confused about what your skin actually needs? Mrs. Derm (aka Melissa Coleman) — skincare educator, content creator, and wife of a prominent New Orleans dermatologist — has built her following on refusing to play that game, translating the confusing, expensive world of dermatology into advice women can actually use, and this week she's telling Molly and Emese exactly what's worth it and what's marketing noise. Rather than chase every new device or serum, she breaks down why her own routine is almost aggressively simple, and why the actives that get real results are the boring, consistent ones — not the expensive ones.  She gets refreshingly honest about everything from red light masks and RF microneedling to fillers, facelifts, fat transfer, and the skincare products that are actually worth your money. Mrs. Derm also walks through how watching procedures up close for years changed the way she thinks about surgery, fillers, and when "waiting it out" stops making sense, and makes her case for the one product she believes converts everyone who commits to it. A Sony Music Entertainment production.  Find more great podcasts from Sony Music Entertainment at sonymusic.com/podcasts and follow us at @sonypodcasts  To bring your brand to life in this podcast, email podcastadsales@sonymusic.com Mentioned in the Episode: https://shopmy.us/shop/collections/7539050  Learn more about your ad choices. Visit podcastchoices.com/adchoices

View WCN's video coverage of these meetings online at wilsoncountynews.com/meeting-coverage/. Commissioners Sept. 14 St. Hedwig City Council Sept. 10 Floresville City Council Sept. 9 Floresville EDC Sept. 9 China Grove City Council Sept. 3 China Grove City Council Meeting: Regular meeting, Sept. 3, 7:01-10:17 p.m. https://youtube.com/live/MWk0pxvxmgc Actions: •Approved the minutes of the regular city council meeting of Aug. 6 •Approved to adopt a no-new-revenue property-tax rate for 2026 of 25.4550 cents per 0 of taxable value •Approved a professional services agreement with EMC Strategy Group LLC for grant development and strategic funding services with an amendment requiring EMC to report... Article Link

First treatment approved for Alexander disease; Hyrnuo and Etcamah are approved for lung cancer and breast cancer, respectively; Pelacarsen misses endpoint in the phase 3 HORIZON trial, and atogepant shows promise from relieving menstrual migraines.   

Science Director for the Center for Food Safety Bill Freese joins Lisa Dent to talk about how the Trump Administration is being sued for approving the use of a pesticide containing the “forever chemical,” trifludimoxazin, which has links to cancer, when growing a wide variety of foods.

Our heroes have done it, they have completed their Wisp Walk and come face to face with the being known as "The Mother". As part of this revelation they once more came face to face with the Shibboleth. Some how these interdimensional beings have plans for this planet as well. What are the Shibboleth planning? Are Cas or the Beholder Collective involved? And how will the Phoenix Pham get back quickly to Haven to warn the Wispkin? Hexcrawl Map (link)

We invite you to join Sandy and study from the 2nd Timothy, chapters 2. This time  Sandy reveals the crucial importance of knowing Word of God to be able to teach and equip future generations.You can connect with Moriel in more locations than just YouTube! Check out all our official links on the About page: https://www.youtube.com/c/MorielTVministries/about.The U.S. Copyright Office protects this video and its contents under section 107 of the Fair Use Copyright Act 1976 which can be found here: can be found here: https://www.copyright.gov/title17/92chap1.html#107.While we do encourage comments, all are held for review before posting. We ask that you please focus your posts on the video and it's topic. Keep it relevant to the message; and of course showering us with love is always welcome. We do appreciate you and thank you for caring enough to speak up and speak out.Please note: Posts that are longer than a short paragraph, contains hate, or disrespectful comments, or links to websites or other videos will be deleted. Comments determined to be inappropriate, obscene, disrespectful or with links to pornographic material, will get you banned. All decisions on comments are at our discretion.

It’s the story that’s doing the rounds today and perhaps rightfully so! Today also felt like a game of choose your category; we talked music, art, sports x2, and even pets… something for everyone!Subscribe on LiSTNR: https://play.listnr.com/podcasts/carrie-and-tommySee omnystudio.com/listener for privacy information.

In this video, I walk you through the practical steps of hardware security by physically removing the WiFi and Bluetooth chip from a laptop. This process is essential for anyone looking to create a truly air-gapped system that remains completely isolated from wireless networks. I show you exactly where the module is located and how to safely disconnect it without damaging the rest of your machine. Whether you are building a secure workstation for sensitive data or just want to learn more about computer hardware, this guide provides a clear and direct approach to enhancing your privacy.List of items needed.Laptop for dedicated Air gap deviceComputer with pruned or full node (umbrel or start9 works)M-disc writable driveM-discsUSB flash drivesWebcam if the laptop one doesn't work well enough.Guide I am roughly followinghttps://github.com/bowlarbear/yeti-2.00:29 - Overview: Removing chips vs. BIOS disabling0:50 - Approved communication methods (USB, Disc, Camera)1:16 - Hardware levels and tools (ThinkPad example)2:23 - Step 1: Removing the battery2:45 - Step 2: Accessing the keyboard screws3:15 - Step 3: Removing the keyboard3:24 - Step 4: Locating and removing the Wi-Fi chip3:43 - Step 5: Locating the Bluetooth module (if applicable)4:38 - Pro-tips for hardware disassembly5:25 - The "Simple Method": Disabling via BIOSAir gapped laptop serieshttps://www.youtube.com/playlist?list=PLOqJIdBxn69wBook a 1|1 Bitcoin Consulting call with mehttps://pathtobitcoin.xyz/Join my Bitcoin Learning Community & and access Free Courseshttps://www.skool.com/the-bitcoin-masters-4115/Where I buy Bitcoin (Free BTC & Non-KYC options)https://bitcoinwell.com/referral/bitcoinnotcrypto15% Stampseed Titanium Seed plates (BEST WAY TO STORE BTC PRIVATE KEYS)https://www.stampseed.com/USE CODE : BTCNOTCRYPTO155% off the MicroSeed Stamping kit CODE : HODLhttps://microseed.io/?ref=HODL5% off Start9 servers for plug & play Bitcoin NodesCODE: BNC5https://store.start9.com/Umbrel home for a Bitcoin node and home serverhttps://a.umbrel.com/hodl/umbrel-homeAffordable Privacy Phones & deviceshttps://www.mark37.com/ref/BNC/5% off using code : BNCBuy a Bitforge or Bitaxe here!https://dtvelectronics.com/store/?aff=22Use code hodl for 10% offHardware wallet optionsBlockstream Jadehttps://rewards.blockstream.com/ci9jj4Keystone 3 PRO 5% off using code ForrestHODLhttps://bit.ly/4qfJsVjBitboxhttps://shop.bitbox.swiss/?ref=yfghxxctFree Open Source Bitcoin and Investment tracking toolshttps://plebtools.com/Become a Member of the Channel, Get exclusive content, and livestream playbackhttps://www.youtube.com/channel/UC2aM2gVVEHTu0pfE1ZyA0BQ/joinFollow Rajat, Jor, and I's new show togetherhttps://www.youtube.com/@MapleBitcoinJoin our Communityhttps://www.skool.com/maplebitcoinListen to this as a podcasthttps://podcasters.spotify.com/pod/show/bitcoinnotcryptoFollow me on Nostrnpub1zqm9zant0rxf49wfgw8pt5h0j50cetfes6hwa73u7sxstlzcsz8qh6x9fsFollow on Twitter/Xhttps://x.com/forrestHODLDonate to the show herehttps://coinos.io/BNCVFVSome of the above links may be Affiliate links that support this show at no extra cost to you. None of the links are Sponsored links. This allows me to only promote products and services I personally use and believe in.

The EPA Wants Data Centers To Be Approved In The Dark by Nick Espinosa, Chief Security Fanatic

Anthony Franco joins Darragh McDonald to discuss the approval for a new Rays' stadium in Tampa, whether league expansion could be coming soon, the Orioles claiming Luis Robert Jr. off waivers, and some prospect promotions, including Ethan Salas for the Padres, Walker Jenkins for the Twins, Lazaro Montes for the Mariners, and Leo Bernal for the Cardinals, and how JJ Wetherholt's injury could end up costing St. Louis a PPI draft pick.

We use the Callaway and Good Good Golf controversy to talk about content approval, co-branded risk, and why your apology plan matters more than your apology.Www.the-spacesocial.com

Balancing patient care responsibilities with teaching can be challenging, particularly in busy practice environments where time and resources are limited. This course reviews practical strategies for integrating learners into daily workflow, including delegation, layered learning, and approaches for managing multiple learners. You will be better prepared to create meaningful learning experiences while maintaining efficiency, supporting learner engagement, and reducing the risk of preceptor burnout. HostKate Newman PharmD,Director of Experiential EducationClinical Associate Professor, Pharmacy PracticeSouthern Illinois University - EdwardsvilleGuestDawn Dankenbring, PharmD, BCPSAssistant Director of Experiential Education, Clinical AssistantProfessor of Pharmacy PracticeSIUE School of PharmacyGet CE: CLICK HERE TO CPE CREDIT FOR THE COURSE!CPE Information Learning ObjectivesAt the end of this course, preceptors will be able to:1. Describe strategies for integrating learners into workflow in busy pharmacy practice settings.2. Explain approaches to balancing patient care responsibilities with effective precepting and learner engagement.0.075 CEU/0.75 HrUAN: 0107-0000-26-310-H99-PInitial release date: 8/24/2026Expiration date: 8/24/2029Additional CPE details can be found here.The speakers have no relevant financial relationships with ineligible companies to disclose.The examples shared in this episode are intended to illustrate approaches to experiential learning, service development, and patient care innovation and are not endorsements of any specific service, product, or practice model. Certain examples discussed may no longer be viable, appropriate, or permissible under current regulatory requirements. Pharmacists should exercise professional judgment and ensure compliance with applicable laws, regulations, payer requirements, and evidence-based standards when evaluating or implementing patient care services.This program has been:Approved by the Minnesota Board of Pharmacy as education for Minnesota pharmacy preceptors.Reviewed by the Texas Consortium on Experiential Programs and has been designated as preceptor education and training for Texas preceptors.Follow CEimpact on Social Media:LinkedInInstagram

Changing the numbering system to be more suggestive of a bracket. Sixtus is the third one seed, if you will. Image: Sandro Botticelli, 1480, Pope Sixtus II Popes names Sixtus (originally Xystus): St Sixtus I 117 or 119 to 126 or 128 Martyr St Sixtus II 257 to 258 Famous martyr, in the Roman Canon St Sixtus III 432 to 440 Sixtus IV 1471 to 1484 Sistine Chapel named for him Sixtus V 1585 to 1590 Great reformer of the Papal States and Curia   Sixtus or Xystus I: the earliest pope we have covered so far, in the very uncertain period of the second century, during the reign of Hadrian. The chronicles that look back to this time do not agree on the dates of his ministry and otherwise only record a few vague details. He is supposed to have placed the chanting of the Sanctus at its present place in the Mass, right after the Preface; he is also recorded to have been martyred, although nothing seems to be preserved about the event.   Sixtus / Xystus II: pope during the persecution of Valerian in the third century. His brief reign saw a reconciliation with St. Cyprian and churches in Africa and Asia Minor, which had been requiring heretics to be rebaptized. The persecution was stepped up in August 258 and Pope Xystus was beheaded with four deacons in a cemetery where he was celebrating Mass; two more deacons were executed the same day; the last and most famous deacon, Lawrence, survived a few days to be captured and according to legend roasted to death. Pope Sixtus to this day is mentioned in the full version of the Roman Canon of the Eucharistic Prayer.   Sixtus / Xystus III: prior to his election as pope, a correspondent with St. Augustine. Approved the acts of the Council of Ephesus and rededicated the restored basilica of St. Mary Major. This historical period included continued disputes with both Pelagians and Nestorians. Defended and maintained papal supremacy over Illyricum. Succeeded by Leo the Great.   Sixtus IV: pope of the late fifteenth century. Born of poor parents; became a Franciscan and a notable theologian. Unfortunately once pope he became a traditional nepotist and involved the Papal States in wars to put his nephews in charge of Florence and Ferrara, and wars of this nature continued to absorb papal attention through the beginning of the Reformation. He opposed and annulled the decrees of the Council of Constance and was successful in turning the Church away from conciliarism. He was a great builder and is said to have made Rome much more livable, helping continue its recovery from the Avignon period of the papacy. He reorganized and essentially refounded the Vatican Library and most famously built the Sistine Chapel.   Sixtus V: also of poor birth and Dalmatian ancestry, whose family had fled from Turkish expansion; supposedly a swineherd as a boy. Also became a Franciscan and rose to prominence in that order, also for a time appointed to the Inquisition in Venice. Accompanied the future Gregory XIII to Spain to investigate claims that the Archbishop of Toledo was a heretic, and the two did not get along. During Gregory XIII's long reign he was sidelined. Similarly to his time as an inquisitor, he proved to be an effective but severe and even brutal ruler of the Papal States. He had perhaps ten thousand to thirty thousand brigands to deal with and nearly exterminated them. He put the papal finances in order and built many useful and beautiful buildings, but seems to have taxed the economy into a stupor. Of particular significance, he created fifteen Congregations to organize the cardinals and created much of the current structure of the Curia. He caused editions of the Septuagint and the Vulgate to be printed, although his edition of the Vulgate is not considered to be of high quality, and even at the time was recalled and corrected in 1592 due to many errors already recognized. He was supposedly on the point of forcing the Jesuits to change their name from the "Society of Jesus" and change some of the rules of the order when he died. For a change he was actually notably non-nepotistic.   Why Sixtus VI: A cardinal would take this name in order to revive the memory of Sixtus II (and I), recognizing that the Church in so many parts of the world faces persecution on a massive scale. That by itself might be enough. The early modern era Popes Sixtus, especially Sixtus V, might contribute to the idea especially if 1) the cardinal is a Franciscan and 2) he plans to address the Vatican finances and the organization of the Curia at large.  

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant advancements and regulatory milestones that underscore the industry's commitment to addressing complex health challenges with innovative therapeutics and strategic investments. Eli Lilly has achieved a major breakthrough with the FDA approval of Mounjaro (tirzepatide), a dual GLP-1/GIP agonist designed to reduce cardiovascular risks in individuals with type 2 diabetes. This marks a pivotal step forward in diabetes management, as it not only improves glycemic control but also offers cardiovascular protection. The approval of tirzepatide highlights the therapeutic potential of dual agonists in metabolic disorders, setting a new standard for diabetes care. This development places Eli Lilly at the forefront of incretin-based therapies, a crucial advancement given the high cardiovascular risk associated with diabetes. Priovant Therapeutics has secured its first FDA approval for Lisraya (brepocitinib), a novel TYK2/JAK1 inhibitor tablet aimed at treating dermatomyositis, an autoimmune condition characterized by muscle inflammation and skin rash. As a first-in-class therapeutic option, brepocitinib underscores the growing focus on targeted therapies that modulate specific pathways involved in autoimmune diseases. Priovant's success, following its acquisition from Pfizer, signals its emergence as a significant player in rare disease treatment. Bristol Myers Squibb is making waves with a $173 million investment to construct a second radiopharmaceutical manufacturing facility in Indiana. This strategic move aligns with the increasing demand for precision oncology treatments that utilize radiolabeled compounds for targeted cancer therapy. BMS's investment demonstrates a strong commitment to advancing personalized medicine and meeting future demands in this rapidly evolving field. Gilead Sciences has received FDA approval for Bixlenvo (bictegravir/lenacapavir), an integrase/capsid inhibitor combination pill for virologically suppressed HIV patients. This small molecule therapy offers a potent antiviral strategy by combining two mechanisms of action—integrase inhibition and capsid disruption—enhancing long-term viral suppression for HIV patients. This represents an evolution in HIV treatment, promising improved adherence and patient outcomes. In China, Hutchmed's Atled (fanregratinib) has been approved by the NMPA for treating FGFR2-fusion intrahepatic cholangiocarcinoma after successful Phase 2 trials. Fanregratinib exemplifies precision medicine's approach by targeting specific genetic alterations driving cancer progression, offering new hope for patients with this challenging condition. Cytokinetics has reported promising Phase 3 results for Myqorzo (aficamten) in non-obstructive hypertrophic cardiomyopathy. Aficamten acts as a cardiac myosin inhibitor, representing a novel therapeutic avenue that directly targets the underlying pathophysiology of this rare heart disorder. The positive outcomes from these trials support its bid for FDA approval and could expand treatment options significantly. In respiratory disease research, Generate Bio's GB-0895 has shown encouraging Phase 1 biomarker reductions in chronic obstructive pulmonary disease (COPD). This monoclonal antibody approach targets TSLP and marks progress in developing new therapies for respiratory diseases with high unmet needs. Teva Pharmaceuticals has positioned itself as the stalking horse bidder for BioXcel Therapeutics' neuroscience portfolio amid bankruptcy proceedings. Teva's bid highlights ongoing consolidation trends within the pharmaceutical industry as companies seek to bolster their portfolios through strategic acquisitions. Roche's Genentech announced a substantial deal with DualityBio worth over $1 billion for antibody-drug conjugates (ADCs), focusing on developing treatments for cancers resistant to existing ADC therapies. This partnership showcases Roche's commitment to addressing complex oncology challenges through innovative modalities. Furthermore, AusperBio has secured $120 million in series C funding to advance its oligonucleotide therapy for chronic hepatitis B through Phase 3 trials. Such funding milestones demonstrate robust investor confidence and highlight promising advancements in oligonucleotide therapeutics for chronic infections like hepatitis B. These scientific advancements highlight the dynamic landscape of the biotech and pharmaceutical industries, characterized by innovation-driven solutions across various therapeutic areas. The emphasis on targeted therapies, precision medicine, and strategic investments underscores the sector's dedication to enhancing patient care through cutting-edge science and technology. As these developments unfold, they hold significant potential to impact treatment paradigms, offering hope for improved outcomes across various diseases with high unmet needs. The industry's focus on cutting-edge research and strategic collaborations continues to drive innovations that could redefine therapeutic landscapes globally. Thank you for tuning into Pharma Daily—your source for reliable updates on the evolving world of pharmaceuticals and biotechnology. Join us next time as we continue to explore groundbreaking advancements shaping patient care worldwide.Support the show

Read, Dana, and Chris Trenkmann discuss Hillsborough County commissioners voting 5-2 to approve funding for the Rays' Tampa stadium, while Dana reviews listener feedback on the deal.See omnystudio.com/listener for privacy information.

Vancouver resident Bob Zak questions who authorized the costly Vine Bus station expansion along HWY99, NE 78th St., and Mill Plain, citing low ridership on existing C-TRAN routes and ongoing road disruptions tied to ADA compliance work. https://www.clarkcountytoday.com/opinion/letter-where-did-the-idea-of-expansion-to-the-vine-buses-come-from/ #CTran #TheVine #PublicTransit #Vancouver #ClarkCounty #Transportation #Opinion

Callaway spent three days saying it was disappointed by an ad. Then its CEO admitted Callaway approved that ad before it was posted.This episode is about the gap between those two statements, and what a company reveals when it comments on its own conduct as though it were in the audience for it.A content warning first: the episode discusses domestic violence as an image used in a golf brand campaign. Nobody in this story is accused of real-world violence. The scene was staged. What two companies chose to make, approve and publish is the story.Then the read nobody in the golf feed has: Good Good is not a golf company. It is a media company that raised forty-five million dollars to become one, and the ad was not a lapse in judgment. It was the formula working the way it was paid to work.0:00 — Why the communication is the story0:31 — Three days of being disappointed1:58 — The parody, described once4:07 — Who approved it?7:42 — Statement one: "disappointed by the content that was posted"8:42 — The PGA Tour calls the response late and defensive11:08 — Good Good is not a golf company12:35 — Where the formula came from18:39 — Statement two: "approved by Callaway prior to posting"23:04 — A premiere moves at a sponsor's request24:17 — Forty-five million dollars26:24 — "A 360-degree media company"27:09 — The formula worked the way it was paid to workThe PR Breakdown with Molly McPherson.

Drive with Dr. Peter Attia: Read the notes at at podcastnotes.org. Don't forget to subscribe for free to our newsletter, the top 10 ideas of the week, every Monday --------- View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this episode, Peter returns to the topic of peptides, offering a clear and accessible guide to a field surrounded by both genuine scientific promise and widespread misinformation. Peptides are increasingly marketed for everything from injury recovery and muscle growth to longevity and improved appearance, often with claims that extend far beyond the available evidence. Rather than promoting or dismissing peptides as a category, Peter presents a practical framework for evaluating any peptide: what it is, how it is supposed to work, and where the science is strong, weak, or simply absent. He then applies this framework to a specific example before examining the risks of gray-market products, concerns about sourcing and quality, and where the field may be headed—ultimately helping listeners distinguish legitimate therapies from hope that has been packaged and sold without sufficient evidence. We discuss: What peptides are and why they must be evaluated individually [3:15]; A five-question framework for evaluating peptides and other drugs [5:30]; A three-tier system for classifying the scientific evidence behind peptides [10:00]; Evaluating BPC-157: unclear mechanisms, absent human evidence, and unknown risks [14:00]; Why BPC-157's expanding claims do not indicate a broad mechanism [20:45]; CJC-1295: biological activity versus meaningful clinical benefit [23:30]; Why testimonials about peptide benefits cannot establish the effectiveness of peptides [27:30]; The placebo effect, and the importance of controlled trials for evaluating peptides [31:00]; What FDA approval provides when evaluating peptide safety and effectiveness [34:45]; Why prescriptions from doctors, compounding pharmacies, and third-party testing do not validate unapproved peptides [38:30]; Approved peptides sold on the gray market: why evidence for an approved peptide does not automatically extend to gray-market versions [40:45]; Addressing the claim that pharmaceutical companies ignore effective natural peptides because they cannot be patented [43:00]; The promise of peptide science, and the risks of the gray-market wellness industry [46:30]; Why peptide claims must be falsifiable and why evidence should precede widespread use rather than be expected to catch up later [49:00]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

The Mark Moses Show gives his thoughts on the local city & county have approved the construction of a new baseball stadium for the Tampa Bay Rays to open in 2029.  Mark broadcasts from The Law Offices of Anidjar & Levine Studios. #baseball #mlb #sports #raysup 

LEARN MORE AND REGISTER FOR THE COURSE Insurance credentialing can feel confusing, especially when you're trying to understand applications, contracts, payer enrollment, effective dates, CAQH, NPIs, and all the steps that come after you're approved. In this free continuing education course, Donna Haswell, LCSW, Annie Day, Registered Mental Health Counselor Intern and credentialing and billing expert, and Kym Tolson, LCSW, break down the credentialing process and explain what mental health clinicians need to know to successfully work with insurance in private practice. You'll learn the differences between credentialing, contracting, and enrollment; what information and documentation to have ready before applying; what to look for in payer contracts; how to think about reimbursement rates and product lines; and how to create an organized system for tracking applications, effective dates, recredentialing, and ongoing payer requirements. The presenters also share practical lessons from their own experience helping therapists navigate insurance billing and credentialing, including common mistakes that can delay payment or create problems later. This course is designed for counselors and other mental health clinicians who are starting, growing, or maintaining an insurance-based private practice. Earn 1 NBCC continuing education contact hour. This course is brought to you free of charge by Berries and Bill Like A Boss. FREE Continuing Education, brought to you by Berries.

Today on AirTalk: LAHSA latest (0:30) Dealing with emotional sensitivity (20:11) Meta settlement (51:02) AI op-ed Writing (1:09:02) TV Talk (1:25:29) Visit www.preppi.com/LAist to receive a FREE Preppi Emergency Kit (with any purchase over $100) and be prepared for the next wildfire, earthquake or emergency.

It's Thursday, August 27. Here are today's top stories around Central Indiana. Want to go deeper on the stories you hear on WFYI News Now? Visit wfyi.org and follow us on social media to get local news every day. WFYI News Now is hosted by Barb Anguiano and produced by Zach Bundy. Subscribe wherever you get your podcasts.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Let's dive right into today's top stories, where pioneering advancements and strategic shifts are reshaping how we understand and treat complex diseases. In recent developments, Akeso's PD-1xVEGF bispecific antibody ivonescimab is making waves beyond its initial use in non-small cell lung cancer. The successful completion of a Phase 3 trial for biliary tract cancer marks a pivotal moment, suggesting broader applications of this dual-targeting therapy. Ivonescimab's mechanism—enhancing immune response while inhibiting tumor angiogenesis—could significantly improve patient outcomes across various cancers. However, questions about its efficacy continue to prompt careful scrutiny as it challenges existing treatment paradigms. Regulatory dynamics are equally compelling, with the FDA undergoing potential restructuring under President Trump's nominee for commissioner. The creation of two new deputy commissioner roles is speculated to enhance oversight and accelerate drug approval processes. Such changes are crucial as the FDA navigates increasing demands for rapid evaluations amidst complex pharmaceutical landscapes. Meanwhile, Teva Pharmaceutical Industries finds itself under a competition probe in Turkey, highlighting global antitrust challenges within the industry. As Teva juggles its dual role as a generics leader and an innovator, this scrutiny underscores the delicate balance of maintaining market dominance while adhering to fair competition laws. On the safety front, Baxter International has initiated recalls of two medical products due to particulate contamination concerns. This action underscores the critical importance of rigorous quality control in safeguarding patient trust and safety. Similarly, Vitruvias Therapeutics has recalled thyroid tablets labeled "superpotent," emphasizing precision's vital role in pharmaceutical manufacturing. Eli Lilly is expanding its focus on obesity treatment through Medicare access campaigns for GLP-1 receptor agonists. By targeting older adults, Lilly aims to address obesity as a chronic condition requiring sustained intervention, potentially enhancing health outcomes for millions. Public health remains a pressing concern as Pennsylvania reports its first measles-associated deaths in decades amid rising nationwide cases. This situation highlights the ongoing need for robust vaccination campaigns and public health strategies to combat vaccine-preventable diseases effectively. Cybersecurity is also at the forefront, with Boston Scientific experiencing disruptions from a cyberattack. This incident reflects a broader trend affecting medtech firms globally, underscoring the necessity for robust cybersecurity measures to protect sensitive data and ensure uninterrupted healthcare services. Strategic collaborations continue to drive innovation. SK Biopharmaceuticals' $795 million deal with Biohaven Pharmaceuticals aims to accelerate epilepsy therapy development targeting KV7 ion channels. Such partnerships exemplify how strategic investments can expedite drug development timelines and bring promising therapies to market faster. LabCorp's launch of a new hepatitis D test represents an advancement in diagnostic capabilities, aiming to identify patients with severe viral infections earlier, potentially leading to more timely interventions and better management of complications. Shifting our focus back to oncology, Revolution Medicines has achieved FDA approval for daraxonrasib, a RAS inhibitor targeting metastatic pancreatic cancer. With compelling data presented at ASCO, this approval signifies a breakthrough in treating RAS mutations—a challenging target implicated in many cancers. The drug's direct inhibition of mutated KRAS proteins disrupts cancer cell proliferation pathways considered "undruggable" until now. The implications are profound: daraxonrasib not only offers hope to patients with limited options but also sets new benchmarks for future RAS-targeted therapy development. It highlights precision medicine's growing trend—tailoring treatments based on genetic profiles to enhance effectiveness while minimizing side effects. In another significant advancement, Jazz Pharmaceuticals' Ziihera (zanidatamab) has been approved by the FDA as a first-line HER2-targeted therapy for gastroesophageal adenocarcinoma. This bispecific antibody represents a promising new class of treatment, enhancing options for patients with this aggressive cancer type and underscoring personalized medicine's importance in oncology. As we conclude today's update, these developments showcase how scientific breakthroughs, regulatory adaptations, and strategic collaborations collectively shape the future landscape of drug development and patient care globally. The industry remains dynamic as it navigates complexities while striving for innovative solutions that promise better health outcomes across diverse medical conditions. Stay tuned for more updates on Pharma Daily as we continue bringing you insights into the ever-evolving world of pharmaceuticals and biotechnology.Support the show

Send Zorba a message!Zorba discusses the FDA's approval of the first mRNA flu vaccine, and how leadership in Washington DC will likely respond. He also talks about his recent humanitarian trip to India, and his visit (and his longtime friendship) with the Dalai Lama. A listener asks if Zorba is eating lettuce right now. We hear a mom joke and we deliver our first ever "corn report."Support the showProduction, edit, and music by Karl ChristensonSend your question to Dr. Zorba (he loves to help!):Phone: 608-492-9292 (call anytime)Email: askdoctorzorba@gmail.comWeb: www.doctorzorba.orgStay well!

Send Zorba a message!Zorba discusses the FDA's approval of the first mRNA flu vaccine, and how leadership in Washington DC will likely respond. He also talks about his recent humanitarian trip to India, and his visit (and his longtime friendship) with the Dalai Lama. A listener asks if Zorba is eating lettuce right now. We hear a mom joke and we deliver our first ever "corn report."Support the showProduction, edit, and music by Karl ChristensonSend your question to Dr. Zorba (he loves to help!):Phone: 608-492-9292 (call anytime)Email: askdoctorzorba@gmail.comWeb: www.doctorzorba.orgStay well!

Scientists have used AI to find a possible cure for skin cancer. Why do so many people polled say they won't take it? Bruce and Gaydos discuss.

You press play, pass the quiz, and add another CE to your collection. But have you ever wondered what it takes for that education to become CE-approved in the first place? In this Season 33 finale episode, Bobby and Jason are turning the mic to Beyond Clean's Chelsea Schmitz for a behind-the-scenes look at how continuing education programs become CE-approved. With more than 500 CE submissions under her belt, Chels walks through how educational content goes from an idea to an approved CE, what it takes to maintain CE-approved content, and what separates meaningful education from another hour spent checking a requirement off the list. We're closing out a season dedicated to training in SPD with a look at what goes into the education that keeps #CleanFreaks and our industry moving forward. Don't miss this season finale! After finishing this podcast episode, earn your 1 CE credit immediately by passing the short quiz linked here: https://www.flexiquiz.com/SC/N/episode33-08 Visit our CE Credit Hub at https://www.beyondcleanmedia.com/ce-credit-hub to access this quiz and over 350 other free CE credits. #BeyondClean #SterileProcessing #Season33 #BuiltDifferent #TrainingInSPD #CE #ContinuingEducation #CEApproved #Education

PJ talks to Helen who is raging that people like 16 year old Paudie Coady and Emma O'Shea have to plead for Skyclarys to be approved. Hosted on Acast. See acast.com/privacy for more information.

It's just two brief words in Billy Joel's rapid-fire historical anthem, We Didn't Start the Fire, but it represents one of the most seismic cultural shifts of the 20th century. In this episode of History Ignited, we're unpacking the invention and explosive impact of the birth control pill.Approved by the FDA in the early 1960s, the first oral contraceptive was a medical marvel that fundamentally altered the fabric of modern life. We explore how "The Pill" catalyzed the sexual revolution, transformed women's access to higher education and the workforce, and sparked intense political and social debates that continue to this day.Join us as we explore the trailblazers who fought for its approval, the science behind its creation, and the lasting legacy of the little pill that changed the world.Send us Fan MailAbout History Ignited: History Ignited is the award-winning kids and family history podcast inspired by Billy Joel's We Didn't Start the Fire. Each short episode explores the real stories behind the people, events, inventions, and cultural moments that shaped the world from the 1950s through the 1980s. Winner of the 2025 Webby People's Voice Award for Best Kids & Family Podcast.

Ep 96- Witches are the hot topic and 2 aldermen meetings that didnt disappoint! If you like what your listening too, please subscribe and if don't mind, leave a positive review on your podcast app! We do not own the rights to any music used but sure enjoy the great sounds! Social Media : X @utwpod FB @utwpodcast email: underthewatertowerinfo@gmail.com Sponsors that make show happen: Brian Couch of Team Couch of Burch Realty - Teamcouch.com office 662-449-1700 Cell 901-461-7653 Alley Ejlali Alfa Insurance - Office number 662-893-0928, Cell 1-843-324-0930  Desoto PC - 662-399-2400  Desoto Family Dental Care 662-429-5239 Michael Hatcher & Associates (901) 755-3207 Hatcherlandscape.com Salt Chapel wedding venue and event center- Saltchapel.com 662-278-0198 **

LA's mayor tries to fend off her challenger in a heated debate. A controversial wildfire policy gets approved. And several reporters and military members were detained at gunpoint at California military base. Support The L.A. Report by donating at LAist.com/join and by visiting https://laist.comSupport the show: https://laist.com

OB448: Missed Approach Approved  Released to show supporters on 8/3/2026 Public release scheduled for 8/19/2026 Have a great week, and thanks for listening to Opposing Bases Air Traffic Talk! ✈️ Real pilots. Real controllers. Real talk.

2 Timothy 3:14-19 (ESV)Andrew and Edwin discuss how to be a worker that doesn't need to be ashamed, by handling the Word correctly.Read the written devo that goes along with this episode by clicking here.    Let us know what you are learning or any questions you have. Email us at TextTalk@ChristiansMeetHere.org.    Join the Facebook community and join the conversation by clicking here. We'd love to meet you. Be a guest among the Christians who meet on Livingston Avenue. Click here to find out more. Michael Eldridge sang all four parts of our theme song. Find more from him by clicking here.   Thanks for talking about the text with us today.________________________________________________If the hyperlinks do not work, copy the following addresses and paste them into the URL bar of your web browser: Daily Written Devo: https://readthebiblemakedisciples.wordpress.com/?p=26530The Christians Who Meet on Livingston Avenue: http://www.christiansmeethere.org/Facebook Page: https://www.facebook.com/TalkAboutTheTextFacebook Group: https://www.facebook.com/groups/texttalkMichael Eldridge: https://acapeldridge.com/ 

Ben & Woods kick off the 7am hour with some more thoughts on last night's loss to the Mets, and we discuss the Padres sale / transfer of ownership being unanimously approved yesterday! Then we get to "Don't (And DO) Do This" before we are joined by Padres broadcaster Jesse Agler who calls in from New York to give us his perspective on last night's game. Listen here!

I'm finally baaaaaaack! And this one's JUICY.

Bad hires cost advisory firms upwards of three times salary in direct and indirect costs. But the real issue isn't always the person, it's the system. When firms grow fast and operate under pressure, they hire quickly without clear role definition, leading new hires to navigate confusion, tribal knowledge, and conflicting expectations. Ray Sclafani explores why onboarding cannot be a first-day checklist in advisory firms where work is technical, judgment-dependent, and outcomes matter. The solution is building a better receiving system before the candidate arrives, starting with role clarity.In this episode, you'll learn the eight-question framework, the 100-Day Role Clarity Map, that separates successful hires from failed ones. You'll also discover why structuring the first 100 days into three distinct phases dramatically improves outcomes, how to assign decision rights without confusion, and why your employee value proposition is as critical as your client value proposition. By the end, you'll have a practical template to use before your next hire and coaching questions to lead your leadership team through the design process.This framework applies to advisory firms of all sizes and maturity levels, and it's grounded in research from Korn Ferry and SHRM that shows structured onboarding directly correlates with retention, performance, and firm growth.WHAT YOU'LL LEARN IN THIS EPISODEThe true cost of a bad hire and why good hires in confused systems fail faster than bad hires in clear onesThe eight critical questions every role must answer to ensure successWhy decision rights are non-negotiable and how to assign themHow to structure the first 30, 60, and 100 days into measurable milestonesThe connection between employee value proposition and retentionTHE 100-DAY ROLE CLARITY MAPWhy does this role exist? (Purpose and problem it solves)What outcomes define success? (Not activities, outcomes)What decisions can this person make? (Independent, approval, escalation)Who are the key relationships? (Manager, mentor, buddy, stakeholders)What should happen in the first 30 days? (Context-building phase)What should happen by day 60? (Ownership and feedback phase)What should happen by day 100? (Readiness and coaching phase)What AI tools and guardrails apply to the role? (Approved tools, data rules, review requirements)REFLECTION QUESTIONS FOR YOUR LEADERSHIP TEAMWhat would each new hire need to understand in their first hundred days to maximize their impact?How are you measuring the quality of hire after the employee starts?Which parts of your onboarding process today still rely too heavily on informal tribal knowledge?What changes or improvements can you make to your employee value proposition, including a presentation deck that you share with prospective and current employees?How will AI expectations be communicated to every new hire before habits form?Building the Billion Dollar Business is hosted by Ray Sclafani, Founder and CEO of ClientWise, the financial services industry's leading executive coaching and team development firm for elite advisors and wealth management teams.Find Ray and the ClientWise Team on the ClientWise website or LinkedIn | Twitter | Instagram | Facebook | YouTube

Apple Intelligence. Approved by Beijing. by Nick Espinosa, Chief Security Fanatic

A man disguised as a peddler stands on the bank of the Yangtze watching a British fleet go past, and tries to hitch a ride to Nanjing. He's been trying to reach the rebel capital for 6 years now, and this is the closest he's gotten. He's told “no” … again. So he picks himself up once more and just keeps walking. He'll get there eventually. And once he does, within three weeks he'll be made the Shield King – the 2nd most powerful man in the Taiping Kingdom… on paper, at least. Time Period Covered:1858–1859 CE Major Historical Figures: Taiping Heavenly Kingdom:Hong Xiuquan, the Heavenly King [1814–1864]Hong Rengan, the Shield King [1822–1864]Chen Yucheng, the Brave King [1837–1862]Li Xiucheng, the Loyal King [1823–1864]Shi Dakai, the Wing King [1831–1863] Great Britain:James Bruce, 8th Earl of Elgin [1811–1863]Thomas Francis Wade, interpreter [1818–1895] Missionaries & Observers:Theodore Hamberg [1819–1854]James Legge [1815–1897]Karl Marx [1818–1883] Great Qing:The Xianfeng Emperor (Aisin-Gioro Yizhu) [r. 1850–1861]Magistrate Tan of Huangmei Major Works Cited:Hamberg, Theodore. The Visions of Hung-Siu-tshuen, and Origin of the Kwang-si Insurrection.Kuhn, Philip A. "The Taiping Rebellion" in The Cambridge History of China, Vol. 10.Michael, Franz, and Chung-li Chang. The Taiping Rebellion: History and Documents, Vols. I, II & III.Oliphant, Laurence. Narrative of the Earl of Elgin's Mission to China and Japan in the Years 1857, '58, '59.Platt, Stephen R. Autumn in the Heavenly Kingdom: China, the West, and the Epic Story of the Taiping Civil War. Spence, Jonathan D. God's Chinese Son: The Taiping Heavenly Kingdom of Hong Xiuquan. Learn more about your ad choices. Visit megaphone.fm/adchoices

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this episode, Peter returns to the topic of peptides, offering a clear and accessible guide to a field surrounded by both genuine scientific promise and widespread misinformation. Peptides are increasingly marketed for everything from injury recovery and muscle growth to longevity and improved appearance, often with claims that extend far beyond the available evidence. Rather than promoting or dismissing peptides as a category, Peter presents a practical framework for evaluating any peptide: what it is, how it is supposed to work, and where the science is strong, weak, or simply absent. He then applies this framework to a specific example before examining the risks of gray-market products, concerns about sourcing and quality, and where the field may be headed—ultimately helping listeners distinguish legitimate therapies from hope that has been packaged and sold without sufficient evidence. We discuss: What peptides are and why they must be evaluated individually [3:15]; A five-question framework for evaluating peptides and other drugs [5:30]; A three-tier system for classifying the scientific evidence behind peptides [10:00]; Evaluating BPC-157: unclear mechanisms, absent human evidence, and unknown risks [14:00]; Why BPC-157's expanding claims do not indicate a broad mechanism [20:45]; CJC-1295: biological activity versus meaningful clinical benefit [23:30]; Why testimonials about peptide benefits cannot establish the effectiveness of peptides [27:30]; The placebo effect, and the importance of controlled trials for evaluating peptides [31:00]; What FDA approval provides when evaluating peptide safety and effectiveness [34:45]; Why prescriptions from doctors, compounding pharmacies, and third-party testing do not validate unapproved peptides [38:30]; Approved peptides sold on the gray market: why evidence for an approved peptide does not automatically extend to gray-market versions [40:45]; Addressing the claim that pharmaceutical companies ignore effective natural peptides because they cannot be patented [43:00]; The promise of peptide science, and the risks of the gray-market wellness industry [46:30]; Why peptide claims must be falsifiable and why evidence should precede widespread use rather than be expected to catch up later [49:00]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

Welcome to the land podcast, a platform for people looking to educate themselves in the world of land ownership, land investing, staying up to date with current land trends in the Midwest, and hearing from industry experts and professionals. On today's episode, we are back in the studio with Mike Cantrall. We discuss: Why two years of house-loan rejections came down to being newly self-employed and a DTI formula. How Mike found a lender who looks at the whole financial picture instead of a W-2. The Roth IRA withdrawal that covered his down payment when income alone wouldn't get him approved. Going self-employed with no college degree, no plan, and two deer dropped off at a friend's shop. Why the pressure of working for yourself is what finally forced him to figure out land ownership. How he got pre-approved first, and had a landowner call him about 40 acres the very next day. Buying, improving, and selling his first farm inside four months — and why he skipped the 1031. Why he walked away from a 500-acre lease that cost about what a farm payment does. What a permanent CREP easement restricts, plus the DNR visit that comes with owning one. Why two used car payments a month is roughly the cost of a small farm. And so much more! Chapters: 00:00 Intro 01:00 Starting a Taxidermy Business 04:19 Financing Land While Self-Employed 10:46 Mindset for Land Ownership 13:56 First Farm Purchase Strategy 17:40 Leasing Versus Owning Land 22:25 Rapid Farm Transactions 30:31 1031 Exchange Lessons 34:43 Reflections and Lessons Learned 41:26 Future Plans and CREP 50:37 The Home Building Challenge 53:05 Final Advice and Outro Thanks again for all of the support from our partners—none of this would've been possible without them! Buck Land Funding: https://www.firstbankers.com/bucklandfunding Hawke Optics | Use Code WHTL for 15% off: https://bit.ly/hawkeoptics_ OnX: https://bit.ly/onX_Hunt Painted Arrow: bit.ly/PaintedArrow Latitude Outdoors: https://www.latitudeoutdoors.com/ Whitetail Master Academy https://www.whitetailmasteracademy.com Use code 'HOFER' to save 10% off at www.theprairiefarm.com Massive potential tax savings: ASMLABS.Net

The Pour Over is a Christ-first, politically neutral news podcast. Every Monday, Wednesday, and Friday, we cover the day's biggest stories in ~10 minutes, and pair the biggest headlines with brief biblical reminders. Every Saturday, TPO Explains does a shallow dive into your most-asked questions. On today's episode: How do mRNA vaccines work? Available to watch on Spotify and YouTube ⁠here.⁠ Submit your questions for Jason here. You can find a graphic showing how traditional vaccines work compared to mRNA vaccines here. Looking to support us? You can choose to pay ⁠here⁠. Thanks to our sponsors: The Voice of the Martyrs: Give a Village Outreach Kit | vom.org/TPO Wild Alaskan: $35 off your first box | code: TPO Quince: Free shipping | quince.com/tpo AdelFi: Apply for the Harvest Bundle | https://adelfibanking.com/pourover Upside: extra 25 cents back for every gallon on your first tank of gas | code: TPO LMNT: free 8-pack with purchase | https://links.thepourover.org/LMNT_Podcast Mosh: 25% off first variety pack + 20% off subscription | code: TPO25 Serving Orphans Worldwide: Give a gift to feed a child for a month | https://servingorphans.org/thepourover MORE FROM TPO: ⁠Free newsletter⁠ ⁠Watch TPO on YouTube⁠ ⁠Download the TPO App⁠ Unless otherwise noted, all scripture references are from the Christian Standard Bible (CSB) translation. Learn more about your ad choices. Visit megaphone.fm/adchoices

Special Message from the Office of Approved Opinions Regarding the Ceuta Incident - Konstantin Kisin Triggernometry is proudly independent. Thanks to the sponsors below for making that possible: - We use Ground News to escape the echo chamber and stay fully informed. Go to https://ground.news/triggernometry to save 40% on the Ground News unlimited access Vantage plan. Konstantin X / Twitter - https://x.com/KonstantinKisin Konstantin Substack - https://substack.com/@konstantinkisin Join our exclusive TRIGGERnometry community on Substack! https://triggernometry.substack.com/ OR Support TRIGGERnometry Here: Bitcoin: bc1qm6vvhduc6s3rvy8u76sllmrfpynfv94qw8p8d5 Shop Merch here - https://shop.triggerpod.co.uk/ Advertise on Triggernometry: https://trigger-brands.com | or enquire at marketing@triggerpod.co.uk Find TRIGGERnometry on Social Media: https://twitter.com/triggerpod https://www.facebook.com/triggerpod/ https://www.instagram.com/triggerpod/ About TRIGGERnometry: Stand-up comedians Konstantin Kisin (@konstantinkisin) and Francis Foster (@francisjfoster) make sense of politics, economics, free speech, AI, drug policy and WW3 with the help of presidential advisors, renowned economists, award-winning journalists, controversial writers, leading scientists and notorious comedians. Learn more about your ad choices. Visit megaphone.fm/adchoices